Lucintel Forecasts the Global Liquid Biopsy Market to Reach $9 Billion by 2030
Lucintel Forecasts the Global Liquid Biopsy Market to Reach $9 Billion by 2030
Blog Article
According to the recent study the global liquid biopsy market is projected to reach an estimated $9 billion by 2030 from $4 billion in 2023 at a CAGR of 12.5% from 2023 to 2030. Growth in this market is primarily driven by increasing prevalence of cancer, preference for non-invasive procedures, and increasing need of early detection of high precision diseases in real time.
Browse 163 figures/charts and 129 tables in this 264-page report to understand trends, opportunities and forecast in global liquid biopsy market by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end uses), and region (North America, Europe, Asia Pacific, and the Rest of the World).
“Circulating Tumor DNA (CtDNA) market is expected to remain the largest segment during the forecast period.”
Based on circulating biomarker, the liquid biopsy market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers. Lucintel forecasts that the circulating tumor DNA (ctDNA) market is expected to remain the largest segment and is also expected to witness the highest growth over the forecast period due to increasing use of ctDNA biomarkers in next-generation sequencing (NGS) technologies for detecting diseases in real time and in early stage.
“Within the automotive suspension market, the therapy selection segment is expected to remain the largest clinical application.”
Based on clinical application, the therapy selection segment is expected to witness the highest growth over the forecast period due to its offerings of various benefits, such as non-invasiveness, access to tumor heterogeneity, real-time treatment monitoring, and recurrence detection in advance of significant tumor formation or metastasis.
“Asia Pacific will dominate the liquid biopsy market in near future.”
Asia Pacific is expected to largest region and is also expected to witness the highest growth over the forecast period due to rising non-invasive treatment, a rising incidence of cancer, and improving healthcare infrastructure.
Major players of liquid biopsy market are adopting various growth strategies like new product launches, expansions, merger and acquisitions, partnerships, agreements, and collaborations to expand their presence in this market. Guardant, Bio-Rad Laboratories, Qaigen, MDxHealth, Myriad Genetics, Biocept, Roche, Illumina, and Thermofisher are among the major liquid biopsy providers.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/liquid-biopsy-market.aspx or helpdesk@lucintel.com.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times. For further information, visit www.lucintel.com.
Contact:
Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: brandon.fitzgerald@lucintel.com
Tel. 972.636.5056
Cell: 303.775.0751